Imatinib Mesylate

newly diagnosed, chronic phase Chronic myeloid leukemia, Metastatic Gastrointestinal Stromal Tumor, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia + 20 more

Treatment

21 FDA approvals

20 Active Studies for Imatinib Mesylate

Treatment for

newly diagnosed, chronic phase Chronic myeloid leukemia

What is Imatinib Mesylate

ImatinibThe Generic name of this drug

Treatment SummaryImatinib is a cancer-fighting medicine used to treat several types of cancer. It is sold under the brand names Gleevec and Glivec. Imatinib works by blocking certain enzymes, which prevents tumor growth. This is the first drug of its kind, as it specifically targets cancer cells instead of just any rapidly dividing cells.

Gleevecis the brand name

image of different drug pills on a surface

Imatinib Mesylate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Gleevec

Imatinib

2001

Approved as Treatment by the FDA

Imatinib, also called Gleevec, is approved by the FDA for 21 uses including Metastatic Gastrointestinal Stromal Tumor (GIST) and Blast Phase .

Metastatic Gastrointestinal Stromal Tumor (GIST)

Blast Phase

Accelerated Phase Chronic Myelogenous Leukemia (CML)

recurrent Dermatofibrosarcoma protuberans

newly diagnosed, chronic phase Chronic myeloid leukemia

Myelodysplastic Syndrome

FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome

unresectable Gastrointestinal stromal tumor

metastatic Dermatofibrosarcoma protuberans

Myeloproliferative Disorders (MPD)

Metastatic Gastrointestinal Stromal Tumor

refractory, chronic phase Chronic myeloid leukemia

FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia

newly diagnosed Acute Lymphoblastic Leukaemia

Mastocytosis, Systemic

Hypereosinophilic Syndrome (HES)

Eosinophilic leukemia

Gastrointestinal Stromal Tumors

Refractory Acute Lymphoblastic Leukemia (ALL)

Leukemia, Myeloid, Accelerated Phase

Effectiveness

How Imatinib Mesylate Affects PatientsImatinib is a medicine used to treat certain types of cancer. It works by blocking the activity of certain proteins (called tyrosine kinases) that help cancer cells grow and divide. Imatinib specifically targets a protein called BCR-ABL, which is involved in many processes that cause cancer cells to grow and spread. Normal cells are usually not affected by imatinib because they have other proteins that can take over the job of the blocked protein. But cancer cells rely heavily on BCR-ABL, so they are more likely to be impacted by imatinib.

How Imatinib Mesylate works in the bodyImatinib mesylate is a drug that stops cancer cells from growing and spreading. It does this by blocking a protein called BCR-ABL, which is found in higher amounts in cancer cells. Imatinib also targets the proteins that help cancer cells survive, such as PDGF and SCF, by blocking their activity. In lab tests, imatinib has been shown to stop the growth of cancer cells and even cause them to die.

When to interrupt dosage

The measure of Imatinib Mesylate is contingent upon the determined ailment, including Metastatic Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome (HES) and Desmoid Tumors. The amount of dosage is contingent upon the method of delivery specified in the table below.

Condition

Dosage

Administration

recurrent Dermatofibrosarcoma protuberans

400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg